Compare Stocks → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADXSNASDAQ:ENVBNASDAQ:PULMNASDAQ:SHPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.30$0.56$0.14▼$1.95$3.23M1.6320,317 shs3,379 shsENVBEnveric Biosciences$0.83+1.2%$0.96$0.65▼$6.98$6.42M0.823.08 million shs72,155 shsPULMPulmatrix$2.00+1.5%$1.87$1.55▼$2.91$7.30M0.916,606 shs23,533 shsSHPHShuttle Pharmaceuticals$0.41$0.42$0.35▼$2.75$6.98M-1.18102,862 shs27,611 shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals+36.36%+42.86%-47.55%-61.93%-58.33%ENVBEnveric Biosciences-2.21%-3.31%-6.72%-5.14%-76.80%PULMPulmatrix+1.57%+8.99%-2.50%+9.30%-31.81%SHPHShuttle Pharmaceuticals+4.57%+4.67%+8.50%+9.52%-59.34%Warren Buffett's "mystery stock" (Ad)WARNING: Read This Before the Next Fed Meeting Investors are looking to the Fed with high hopes for interest rate relief. Unfortunately, many have no idea there's another major story unfolding right now, one that could be worth $40 trillion. This Wall Street millionaire just stepped forward with all the details, and how it could make some MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AENVBEnveric Biosciences1.9883 of 5 stars3.55.00.00.01.00.00.6PULMPulmatrix1.6422 of 5 stars3.55.00.00.00.00.00.6SHPHShuttle PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals2.00HoldN/AN/AENVBEnveric Biosciences3.00Buy$10.001,107.73% UpsidePULMPulmatrix3.00Buy$10.00400.00% UpsideSHPHShuttle PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$10K322.50N/AN/A($2.27) per share-0.13ENVBEnveric BiosciencesN/AN/AN/AN/A$0.71 per shareN/APULMPulmatrix$7.30M1.00N/AN/A$4.93 per share0.41SHPHShuttle PharmaceuticalsN/AN/AN/AN/A$0.25 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$7.98N/A∞N/AN/A-3,967.23%-339.10%5/21/2024 (Estimated)ENVBEnveric Biosciences-$17.29M-$6.41N/AN/AN/AN/A-383.90%-204.47%8/12/2024 (Estimated)PULMPulmatrix-$14.12M-$2.41N/A∞N/A-75.73%-44.05%-26.71%8/8/2024 (Estimated)SHPHShuttle Pharmaceuticals-$6.59M-$0.46N/A∞N/AN/A-151.82%-109.20%8/12/2024 (Estimated)Latest ADXS, PULM, SHPH, and ENVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/16/2024Q4 2023ADXSAyala PharmaceuticalsN/A-$2.96-$2.96-$2.96N/AN/A3/28/2024Q4 2023PULMPulmatrixN/A-$0.57-$0.57-$0.57N/A$2.20 million3/25/2024Q4 2023ENVBEnveric Biosciences-$1.55-$1.46+$0.09-$1.46N/AN/A3/21/2024Q4 2023SHPHShuttle PharmaceuticalsN/A-$0.10-$0.10-$0.10N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/APULMPulmatrixN/AN/AN/AN/AN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/A0.300.30ENVBEnveric BiosciencesN/A3.483.48PULMPulmatrixN/A5.595.59SHPHShuttle PharmaceuticalsN/A2.962.96OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%ENVBEnveric Biosciences13.82%PULMPulmatrix11.84%SHPHShuttle Pharmaceuticals4.58%Insider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%ENVBEnveric Biosciences1.20%PULMPulmatrix3.61%SHPHShuttle Pharmaceuticals40.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala PharmaceuticalsN/A10.75 million10.68 millionNot OptionableENVBEnveric Biosciences77.75 million7.66 millionNot OptionablePULMPulmatrix223.65 million3.52 millionNot OptionableSHPHShuttle Pharmaceuticals816.80 million9.98 millionNot OptionableADXS, PULM, SHPH, and ENVB HeadlinesRecent News About These CompaniesMay 14, 2024 | finanznachrichten.deShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides First Quarter 2024 Corporate UpdateMay 14, 2024 | globenewswire.comShuttle Pharma Provides First Quarter 2024 Corporate UpdateMay 13, 2024 | investorplace.comSHPH Stock Earnings: Shuttle Pharmaceuticals Reported Results for Q1 2024April 23, 2024 | globenewswire.comShuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024April 3, 2024 | globenewswire.comShuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024March 22, 2024 | finanznachrichten.deShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides Fourth Quarter 2023 Corporate UpdateMarch 22, 2024 | finance.yahoo.comShuttle Pharma Provides Fourth Quarter 2023 Corporate UpdateMarch 22, 2024 | msn.comSHPH Stock Earnings: Shuttle Pharmaceuticals Reported Results for Q4 2023March 5, 2024 | globenewswire.comShuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024February 13, 2024 | thedailyrecord.comRockville’s Shuttle Diagnostics to pursue $4.5M rights offeringFebruary 13, 2024 | finance.yahoo.comShuttle Pharma Announces Its Intent to Pursue a Rights OfferingFebruary 6, 2024 | msn.comShuttle Pharmaceuticals Acquires Promising Prostate Cancer TechnologyFebruary 6, 2024 | msn.comShuttle Pharmaceuticals Bolsters Investor Relations with New PartnershipJanuary 23, 2024 | finance.yahoo.comShuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024January 8, 2024 | finance.yahoo.comShuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with GlioblastomaDecember 11, 2023 | finance.yahoo.comShuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with GlioblastomaNovember 30, 2023 | finance.yahoo.comShuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023November 14, 2023 | msn.comShuttle Pharmaceuticals reports Q3 resultsNovember 14, 2023 | finance.yahoo.comShuttle Pharmaceuticals Provides Third Quarter 2023 Corporate UpdateOctober 31, 2023 | finance.yahoo.comShuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License AgreementNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAyala PharmaceuticalsNASDAQ:ADXSAyala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Enveric BiosciencesNASDAQ:ENVBEnveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.PulmatrixNASDAQ:PULMPulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.Shuttle PharmaceuticalsNASDAQ:SHPHShuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.